Table 1

Late term status after TEVG implantation in clinical trial

Patient

Age at Operation (Years)

Patient Status

Graft Status

Graft Patency

Graft Related Complications

1

2

alive

intact

patent

none

2

1

alive

intact

patent

none

3

7

alive

intact

patent

stenosis

4

21

alive

intact

patent

none

5

4

alive

intact

patent

none

6

12

alive

intact

patent

none

7

17

alive

intact

patent

none

8

19

dead

intact

patent

none

9

3

alive

intact

patent

stenosis

10

2

dead

intact

patent

none

11

13

alive

intact

patent

stenosis

12

2

dead

intact

patent

none

13

2

alive

intact

patent

thrombosis

14

2

alive

intact

patent

none

15

2

alive

intact

patent

none

16

2

alive

intact

patent

none

17

24

alive

intact

patent

none

18

1

alive

intact

patent

stenosis

19

11

alive

intact

patent

none

20

2

alive

intact

patent

none

21

3

alive

intact

patent

none

22

4

alive

intact

patent

none

23

4

alive

intact

patent

none

24

13

alive

intact

patent

none

25

2

dead

intact

patent

none

Most recent follow-up at mean of 5.8 years showed no graft-related mortality and no evidence of aneurysm formation, graft rupture, or ectopic calcification. 4 out of 25 patents developed asymptomatic stenosis that was picked up on routine serial imaging and were successfully treated with angioplasty. All implanted TEVG are currently intact and patent. (Adapted from Hibino (2010) with permission from Elsevier [40]).

Duncan and Breuer Vascular Cell 2011 3:23   doi:10.1186/2045-824X-3-23